The success of Viagra initially fueled a period of growth for major pharmaceutical companies, however recent shifts present a complicated outlook for shareholders. Generic alternatives are reducing revenue, and ongoing litigation add further difficulty to the landscape. While some companies may still see gains from related offerings, the general di